Second Hand Smoke Exposure Associated With Pediatric Anesthesia-Related Airway Complications; Nymox (NASDAQ: NYMX) TobacAlert(TM) Product Detects Second-Hand Smoke Exposure.HASBROUCK HEIGHTS, N.J. -- Nymox Pharmaceutical's (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :NYMX) TobacAlert(TM) product provides an easy-to-use, cost-effective means of on-site testing for second-hand smoke exposure without the need for instruments, equipment or specialized training. A prospective study from Brigham and Women's Hospital Brigham and Women's Hospital (BWH) is a hospital in the Longwood Area of the Boston, Massachusetts neighborhood of Mission Hill. With Massachusetts General Hospital, it is one of the two founding members of Partners HealthCare. , Boston of 405 children undergoing outpatient surgical procedures found that airway complications during anesthesia or postanesthetic recovery were far more common in children subjected to second hand smoke exposure. The study (Otolaryngol Head Neck Surg 2006; 135: 12-6) found intraoperative laryngospasm and airway obstruction were 490% and 280% the incidence for exposed versus non-exposed children. Second-hand smoke poses a serious and pervasive health risk to children and adults according to a new comprehensive report from the U.S. Surgeon General, The Health Consequences of Involuntary Exposure to Tobacco Smoke. The report highlights how vulnerable children in particular are to second-hand smoke. Children exposed to secondhand smoke are at an increased risk for sudden infant death syndrome sudden infant death syndrome (SIDS) or crib death, sudden, unexpected, and unexplained death of an apparently healthy infant under one year of age (usually between two weeks and eight months old). (SIDS SIDS sudden infant death syndrome. SIDS abbr. sudden infant death syndrome SIDS, n See syndrome, sudden infant death. ), acute respiratory infections, ear problems, and more severe asthma. The report also links second-hand smoke to coronary heart disease coronary heart disease: see coronary artery disease. coronary heart disease or ischemic heart disease Progressive reduction of blood supply to the heart muscle due to narrowing or blocking of a coronary artery (see atherosclerosis). and lung cancer in adults and notes that even a brief exposure to second-hand smoke has immediate adverse effects on a person's cardiovascular system. TobacAlert(TM) measures levels of cotinine cotinine (kō´tinēn), n a substance that remains in body fluids after nicotine has been used. Presence of this chemical in body fluids is considered proof of recent nicotine use. , a metabolite of nicotine described in the Surgeon General's Report as "the biomarker of choice for assessing secondhand smoke exposure." Researchers at the Centers for Disease Control and Prevention Centers for Disease Control and Prevention (CDC), agency of the U.S. Public Health Service since 1973, with headquarters in Atlanta; it was established in 1946 as the Communicable Disease Center. (CDC) recently reported positive results using Nymox TobacAlert(TM) technology combined with complex laboratory testing (liquid chromatography-mass spectrometry) used in the CDC laboratory (Journal of Analytical Toxicology November/December, 2005; 29: 814-818). More information is available at www.tobacalert.com. More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669. This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion